What is Theravance Biopharma's EV / sales?

Theravance Biopharma (TBPH) reported EV / sales of 5.4× in Q1 2026.

How has Theravance Biopharma's EV / sales changed year-over-year?

Theravance Biopharma's EV / sales decreased by 7.8% year-over-year, from 5.8× to 5.4×.

What is the long-term trend for Theravance Biopharma's EV / sales?

Over 5 years (2020 to 2025), Theravance Biopharma's EV / sales has grown at a -13.3% compound annual growth rate (CAGR), from 15.6× to 7.7×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

Theravance Biopharma TBPH EV / sales

EV / sales at other companies

Zevra Therapeutics, Inc.ZVRA

3.7×-6.9×

LQD

Liquidia CorporationLQDA

10.8×-66.6×

Royalty PharmaRPRX

11.9×+3.0×

Aurinia PharmaceuticalsAUPH

6.8×+2.2×

PrecigenPGEN

102.1×—

Ultragenyx PharmaceuticalRARE

2.7×-4.0×

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Calculated from Theravance Biopharma’s reported figures.

enterprise value/total revenue=5.4×

Based on the most recent quarter.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's EV / sales?: Theravance Biopharma (TBPH) reported EV / sales of 5.4× in Q1 2026.
How has Theravance Biopharma's EV / sales changed year-over-year?: Theravance Biopharma's EV / sales decreased by 7.8% year-over-year, from 5.8× to 5.4×.
What is the long-term trend for Theravance Biopharma's EV / sales?: Over 5 years (2020 to 2025), Theravance Biopharma's EV / sales has grown at a -13.3% compound annual growth rate (CAGR), from 15.6× to 7.7×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.